【重磅】石药集团首家出击,入局暴涨930%的全球新药

米内网
Jul 09

精彩内容7月8日,石药集团巨石生物制药提交了仑卡奈单抗注射液的3.3类新药临床申请获得CDE承办。仑卡奈单抗是阿尔茨海默症全球新药,2023年获得FDA批准上市,2024年进入中国市场,石药集团是首家入局的国内药企。在神经系统药物市场,石药集团已拥有两个超10亿产品,包括了丁苯酞氯化钠注射液和丁苯酞软胶囊。图1:石药集团最新申报的新药来源:CDE官网图2:仑卡奈单抗的研发情况来源:米内网全球新药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10